NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
Clinical Trials
9 trialsNCT05683834 2025-11-21
Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT04925544 2025-10-21
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University
Phase 2 Active not recruiting
NCT05831111 2025-09-30
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT04645147 2025-07-17
Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT01494103 2025-07-11
DOTTI
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05164094 2025-05-15
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
ModernaTX, Inc.
Phase 1/2 Active not recruiting
NCT03475212 2025-05-11
ACES
Pediatric Transplantation & Cellular Therapy Consortium
Phase 1/2 Active not recruiting
NCT03813394 2024-11-22
2018/00947
National University Hospital, Singapore
Phase 1/2 Active not recruiting